These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1086 related articles for article (PubMed ID: 27198892)

  • 1. Quantitative diffusion-weighted magnetic resonance imaging in the assessment of myocardial fibrosis in hypertrophic cardiomyopathy compared with T1 mapping.
    Wu LM; Chen BH; Yao QY; Ou YR; Wu R; Jiang M; Hu J; An DA; Xu JR
    Int J Cardiovasc Imaging; 2016 Aug; 32(8):1289-97. PubMed ID: 27198892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myocardial fibrosis evaluated by diffusion-weighted imaging and its relationship to 3D contractile function in patients with hypertrophic cardiomyopathy.
    Wu R; An DA; Shi RY; Chen BH; Jiang M; Bacyinski A; Han TT; Hu J; Xu JR; Wu LM
    J Magn Reson Imaging; 2018 Oct; 48(4):1139-1146. PubMed ID: 29601139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffusion-weighted imaging in hypertrophic cardiomyopathy: association with high T2-weighted signal intensity in addition to late gadolinium enhancement.
    Shi RY; An DA; Chen BH; Wu R; Du L; Jiang M; Xu JR; Wu LM
    Int J Cardiovasc Imaging; 2020 Nov; 36(11):2229-2238. PubMed ID: 32666169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T1 mapping in children and young adults with hypertrophic cardiomyopathy.
    Parekh K; Markl M; Deng J; de Freitas RA; Rigsby CK
    Int J Cardiovasc Imaging; 2017 Jan; 33(1):109-117. PubMed ID: 27659477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The apparent diffusion coefficient is strongly correlated with extracellular volume, a measure of myocardial fibrosis, and subclinical cardiomyopathy in patients with systemic lupus erythematosus.
    Wu R; An DA; Hu J; Jiang M; Guo Q; Xu JR; Wu LM
    Acta Radiol; 2018 Mar; 59(3):287-295. PubMed ID: 28679323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Native T1-mapping for non-contrast assessment of myocardial fibrosis in patients with hypertrophic cardiomyopathy--comparison with late enhancement quantification.
    Małek ŁA; Werys K; Kłopotowski M; Śpiewak M; Miłosz-Wieczorek B; Mazurkiewicz Ł; Petryka-Mazurkiewicz J; Marczak M; Witkowski A
    Magn Reson Imaging; 2015 Jul; 33(6):718-24. PubMed ID: 25863138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy: comparison of diagnostic performance in myocardial fibrosis between gadobutrol and gadopentetate dimeglumine.
    Liu D; Ma X; Liu J; Zhao L; Chen H; Xu L; Sun Z; Fan Z
    Int J Cardiovasc Imaging; 2017 Aug; 33(8):1191-1200. PubMed ID: 28289991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous T1ρ cardiovascular magnetic resonance in hypertrophic cardiomyopathy.
    Thompson EW; Kamesh Iyer S; Solomon MP; Li Z; Zhang Q; Piechnik S; Werys K; Swago S; Moon BF; Rodgers ZB; Hall A; Kumar R; Reza N; Kim J; Jamil A; Desjardins B; Litt H; Owens A; Witschey WRT; Han Y
    J Cardiovasc Magn Reson; 2021 Oct; 23(1):120. PubMed ID: 34689798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cellular and extracellular pathology assessed by T1 mapping on regional contractile function in hypertrophic cardiomyopathy.
    Swoboda PP; McDiarmid AK; Erhayiem B; Law GR; Garg P; Broadbent DA; Ripley DP; Musa TA; Dobson LE; Foley JR; Fent GJ; Page SP; Greenwood JP; Plein S
    J Cardiovasc Magn Reson; 2017 Feb; 19(1):16. PubMed ID: 28215181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous assessment of late gadolinium enhancement grey zone in patients with non-ischaemic cardiomyopathy with T1ρ and native T1 mapping.
    Dong Z; Yin G; Yang K; Jiang K; Wu Z; Chen X; Song Y; Yu S; Wang J; Yang S; Ma X; Xu Y; Zhao K; Lu M; Xu X; Zhao S
    Eur Heart J Cardiovasc Imaging; 2023 Mar; 24(4):492-502. PubMed ID: 35793269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrast-free detection of myocardial fibrosis in hypertrophic cardiomyopathy patients with diffusion-weighted cardiovascular magnetic resonance.
    Nguyen C; Lu M; Fan Z; Bi X; Kellman P; Zhao S; Li D
    J Cardiovasc Magn Reson; 2015 Dec; 17():107. PubMed ID: 26631061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3.0 T magnetic resonance myocardial perfusion imaging for semi-quantitative evaluation of coronary microvascular dysfunction in hypertrophic cardiomyopathy.
    Yin L; Xu HY; Zheng SS; Zhu Y; Xiao JX; Zhou W; Yu SS; Gong LG
    Int J Cardiovasc Imaging; 2017 Dec; 33(12):1949-1959. PubMed ID: 28612277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histogram Analysis of Native T
    Wu CW; Wu R; Shi RY; An DA; Chen BH; Jiang M; Bacyinski A; Rahim A; Deen JM; Hu J; Han TT; Xu JR; Wu LM
    J Magn Reson Imaging; 2019 Mar; 49(3):668-677. PubMed ID: 30142234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Native T1 Mapping and Extracellular Volume Mapping for the Assessment of Diffuse Myocardial Fibrosis in Dilated Cardiomyopathy.
    Nakamori S; Dohi K; Ishida M; Goto Y; Imanaka-Yoshida K; Omori T; Goto I; Kumagai N; Fujimoto N; Ichikawa Y; Kitagawa K; Yamada N; Sakuma H; Ito M
    JACC Cardiovasc Imaging; 2018 Jan; 11(1):48-59. PubMed ID: 28624408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The feasibility and diagnostic value of intravoxel incoherent motion diffusion-weighted imaging in the assessment of myocardial fibrosis in hypertrophic cardiomyopathy patients.
    Wu R; An DA; Shi RY; Chen BH; Wu CW; Jiang M; Xu JR; Wu LM; Pu J
    Eur J Radiol; 2020 Nov; 132():109333. PubMed ID: 33068839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocardial extracellular volume fraction measurements with MOLLI 5(3)3 by cardiovascular MRI for the discrimination of healthy volunteers from dilated and hypertrophic cardiomyopathy patients.
    Cui Y; Chen Y; Cao Y; Liu J; Song J; Zhang S; Kong X; Han P; Shi H
    Clin Radiol; 2019 Sep; 74(9):732.e9-732.e16. PubMed ID: 31122714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Value of Myocardial Fibrosis Parameters Derived from Cardiac Magnetic Resonance Imaging in Risk Stratification for Patients with Hypertrophic Cardiomyopathy.
    Yu T; Cai Z; Yang Z; Lin W; Su Y; Li J; Xie S; Shen J
    Acad Radiol; 2023 Sep; 30(9):1962-1978. PubMed ID: 36604228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T
    Maforo NG; Magrath P; Moulin K; Shao J; Kim GH; Prosper A; Renella P; Wu HH; Halnon N; Ennis DB
    J Cardiovasc Magn Reson; 2020 Dec; 22(1):85. PubMed ID: 33302967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI T1 Mapping in Hypertrophic Cardiomyopathy: Evaluation in Patients Without Late Gadolinium Enhancement and Hemodynamic Obstruction.
    Xu J; Zhuang B; Sirajuddin A; Li S; Huang J; Yin G; Song L; Jiang Y; Zhao S; Lu M
    Radiology; 2020 Feb; 294(2):275-286. PubMed ID: 31769741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of native and contrast-enhanced T1 mapping to detect myocardial damage in patients with suspected myocarditis: a head-to-head comparison of different cardiovascular magnetic resonance techniques.
    Nadjiri J; Nieberler H; Hendrich E; Greiser A; Will A; Martinoff S; Hadamitzky M
    Int J Cardiovasc Imaging; 2017 Apr; 33(4):539-547. PubMed ID: 27878700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.